

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number
WO 03/064413 A1

(51) International Patent Classification⁷: C07D 403/12,
471/04, 401/14, 491/04, A61K 31/517, A61P 35/00

Laurent, Francois, Andre [FR/GB]; AstraZeneca R &
D Alderley, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(21) International Application Number: PCT/GB03/00343

(74) Agent: ASTRAZENECA; Global Intellectual Property,
Mereside, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(22) International Filing Date: 28 January 2003 (28.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02290242.3 1 February 2002 (01.02.2002) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE,
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE,
DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM,
GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK, MN,
MW, MX, MZ, NL, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VC, VN, YU, ZA, ZM, ZW only*): ASTRAZENECA R
& D SODERTALJE [SE/SE]; Sodertalje, S-151 85 (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): ASTRAZENECA UK LIM-
ITED [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).

Published:
— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): HENNEQUIN,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 03/064413 A1

(54) Title: QUINAZOLINE COMPOUNDS

(57) Abstract: The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is -O-, -NH- or -S-; n is 0-5; m is 0-3; R¹ and R² are defined herein including groups: (i) Q¹X¹ wherein Q¹ and X¹ are as defined herein; (ii) Q¹⁵W³ wherein Q¹⁵ and W³ are as defined herein, (iii) Q²¹W⁴C₁-salkylX¹- wherein Q²¹, W⁴ and X¹ are as defined herein, (iv) Q²⁸C₁-salkylX¹-, Q²⁸C₂-salkenylX¹- or Q²⁸C₂-salkynylX¹- wherein Q²⁸ and X¹ are as defined herein and (v) Q²⁹C₁-salkylX¹-, Q²⁹C₂-salkenylX¹- or Q²⁹C₂-salkynylX¹- wherein Q²⁹ and X¹ are as defined herein; R² can also be 6,7-methylene-dioxy or 6,7-ethylenedioxy; and salts thereof; their use in the manufacture of a medicament for use in the production of an antian-giogenic and/or vascular permeability reducing effect in warm-blooded animals; processes for the preparation of such compounds; intermediates used in such processes; processes for making such intermediates; pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by admin-istering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of formula I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.